乌拉地尔

A centrally and peripherally-acting alpha-1 adrenergic antagonist with vasodilator effect indicated in the treatment of hypertensive crises. Administration via intravenous infusion for a maximum of one week.

Since the last update we have not found any published data on its excretion in breast milk.

Its pharmacokinetic data ^{(Kirsten 1998 and 1988)} makes it difficult to accurately predict its possible excretion in breastmilk.

Pharmacokinetics show that after 3 elimination half-lives (T½) 87.5% of the drug is eliminated from the body; after 4 T½ it is 94%, after 5 T½, 96.9%, after 6 T½, 98.4% and after 7 T½ it is 99%. From 7 T½ the plasmatic concentrations of drug in the body are negligible. In general, a period of at least five half-lives can be considered a safe waiting period before breastfeeding again. ^{(Anderson 2016)}

Taking as reference the longest published T½ ^{(Kirsten 1988)} these 5 T½ would correspond to 24 hours. To further minimize the risk it may be advisable to stop breastfeeding until 35 hours after the last dose (7 T½). Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable ^{(Kutlesič 2015, Schaefer 2015 p716)}, especially during the neonatal period and in cases of prematurity.